Available Technologies

Executive Summary

MSU and Vanderbilt researchers have found a method for predicting therapeutic response in Parkinson’s disease. The leading treatments, levodopa and deep brain stimulation, are generally effective in treating the motor symptoms of Parkinson’s disease, but the clinical response is highly variable depending on the disease’s genotype. This technology allows doctors to customize medical treatments for Parkinson’s patients, increasing the therapy’s effectiveness for the individual patient.

Description of Technology

Our technology shows that Parkinson’s disease subjects possessing a single nucleotide polymorphism respond differently to optimized drug therapy and deep brain stimulation. As such, we propose that genotyping for this mutation in Parkinson’s disease could serve to inform therapeutic decisions regarding pharmacological vs. surgical management of Parkinson’s disease.

Key Benefits

• Improved treatment- Serves to inform the best therapeutic decision in treating Parkinson’s disease specific to the patient
• Customized medicine—genotyping

Applications

• Personalized medicine for Parkinson’s Disease

Patent Status: 

Patent application published no. 20160319355

Licensing Rights Available

Full licensing rights available

Inventors: Caryl E. Sortwell, Ph.D. Jack W. Lipton, Ph.D. David Charles, M.D. Mallory Hacker, Ph.D.

Tech ID: TEC2015-0077

Alternative contact due to temporary leave:

Nina (Isi) Davis, Technology Marketing Manager, email: davisnin@msu.edu, phone (direct): (517)884-1829.